Key Drivers
- High gross margins
- Strong free cash
- Intangible concentration
AIAI Summary
Enhabit is best treated as a takeover‑arbitrage trade—near‑term upside depends on deal process and litigation outcomes rather than organic growth, since improving hospice cash flow and debt paydown support a higher intrinsic value than Kinderhook's $13.80 bid but CMS cuts, home‑health margin erosion and leverage make holding for a better outcome speculative absent clearer legal wins or operational stabilization.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High gross margins
- •Strong free cash
- •Intangible concentration
EHAB posts strong gross margins and free cash flow with positive annual EBITDA but suffers quarterly profitability volatility, heavy SG&A, large intangible assets and high leverage that weigh on bottom‑line returns.
Price Behavior
Key Price Behavior Insights:
- •Gap higher
- •Narrow consolidation
- •Slightly above average
EHAB has trended up since a gap from $11.09 to $13.62 (≈23%) last month and is now narrowly consolidating just above its short-term average, trading between $13.56–$13.66 with a bullish bias that would resume on a break above $13.66 or reverse if it falls below $13.56.
Sharp jump from $11.09 to $13.62 last month (~23% rise) followed by compressed volatility
Sentiment & News
Key News Insights:
- •Contested buyout
- •Stock surge
- •Matched Q4
Enhabit agreed to a $1.1B all‑cash acquisition at $13.80/share by Kinderhook that sparked multiple shareholder investigations, a 22.6% stock surge and volatile trading despite Q4 results meeting expectations and mixed analyst views.
The deal creates a legal overhang and continued volatility that could pressure share price and potentially prompt renegotiation or litigation outcomes affecting deal value
Similar Companies in Healthcare
Other companies in the same sector with AI ratings